Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How are you integrating Prostox into your practice for prostate patients deciding between SBRT and hypofractionation?
Related Questions
For a patient with stage IIB pure seminoma s/p orchiectomy who has bilateral RP adenopathy, do you also cover the contralateral iliac nodes in the dog-leg field?
How would you plan sequencing of an MRI-directed prostate nodule micro-boost when doing a sequential plan?
How do you incorporate absolute percent pattern 4 (APP4) into your risk stratification, specifically your recommendation for ADT for intermediate prostate cancer?
Would you consider re-irradiation for a prostate local failure for a patient who initially received standard fractionation with a focal SIB to 95 Gy, or a SBRT boost with cyberknife after EBRT?
Is there any evidence for combining surgery and XRT +/- ADT for treatment of localized high risk prostate cancer?
What are the realistic, modern 10-year survival curves for localized prostate cancer given the improvements we have made in diagnostics and treatment?
How do you talk to patients with intermediate-risk prostate cancer deciding between LDR brachytherapy (monotherapy) vs HDR mono vs SBRT vs EBRT, in terms of the comparative side effect profile of each approach?
How do you approach rising PSA following radical prostatectomy and early salvage radiation therapy?
Do you give Ra-223 (Xofigo) to patients diagnosed as having benign neutropenia (ANC 1.0-1.5) who are otherwise eligible to receive this radioisotope?
Is there evidence that prostatectomy improves overall survival in local recurrence of prostate cancer post-definitive radiation?
